Highlights

  • EVE Health Group commenced a pilot pharmacokinetic study for Libbo, an oral soluble film version of vardenafil.
  • The study compares Libbo against an Australian-registered vardenafil tablet in healthy volunteers.
  • Results are expected by the end of September 2026 and will support design of a larger bioequivalence study.
  • EVE reported cash of $1.75 million at 31 March 2026 following a $1.3 million Capital raise.

EVE Health Group (ASX:EVE) has commenced its first clinical study for Libbo, an oral soluble film formulation of the erectile dysfunction medicine vardenafil.

The pilot study, announced on 16 June 2026, compares Libbo against an already registered vardenafil tablet in healthy volunteers and represents the first clinical development step for the product.

The study is designed to generate pharmacokinetic and tolerability data required to plan a larger pivotal bioequivalence trial. While the milestone moves Libbo into clinical evaluation, regulatory registration and commercial launch remain dependent on further development steps.

What Was Announced?

EVE Health Group confirmed the commencement of a pilot pharmacokinetic (PK) study for Libbo, a 10mg vardenafil oral soluble film.

Vardenafil is a PDE5 inhibitor used in established erectile dysfunction treatments. EVE's approach is to reformulate the active ingredient into a film format that dissolves in the mouth rather than being swallowed as a traditional tablet.

The pilot study is being conducted in fasted, healthy male volunteers and compares Libbo's pharmacokinetic profile against an Australian-registered reference vardenafil tablet.

The study is assessing how the drug is absorbed and processed by the body, while also including patient-reported tolerability assessments related to the film format.

EVE expects results by the end of September 2026. The company intends to use the findings to design a larger pivotal bioequivalence study, which would be required to support potential regulatory registration.

Why This Matters

For EVE (ASX:EVE), Libbo represents the company's strategy of reformulating established medicines to create differentiated products through potentially shorter regulatory pathways compared with developing new drug molecules.

The erectile dysfunction treatment market is established, with competition focused on factors such as convenience, delivery format and user experience.

An oral soluble film format aims to provide an alternative method of administration compared with conventional tablets by allowing the product to dissolve in the mouth without requiring water.

However, Libbo remains at an early clinical development stage. The product has not yet completed the pivotal bioequivalence study required for registration, and no commercial partnerships or distribution agreements have been disclosed.

Company Background

EVE Health Group (ASX:EVE) is an Australian life sciences company focused on reformulating established medicines to improve convenience, delivery and user experience.

The company's pipeline includes Libbo, a vardenafil oral soluble film for erectile dysfunction, as well as Dyspro, a gummy-format product targeting dysmenorrhea and endometriosis symptoms.

EVE is also developing a reformulated dapoxetine product for premature ejaculation and a combination vardenafil-and-dapoxetine spray targeting patients experiencing both erectile dysfunction and premature ejaculation.

Ben Rohr was appointed chief executive officer in April 2026, with the company continuing its focus on reformulation-based healthcare products.

Financial Position

EVE's most recent available quarterly Cash Flow report for the quarter ended 31 March 2026 showed cash of $1.75 million, compared with $0.93 million at the start of the quarter.

Operating cash outflow for the quarter was approximately $369,000, while customer receipts were approximately $248,000.

The increase in cash was mainly supported by a net financing inflow of $1.189 million following a $1.3 million capital raise before costs at $0.02 per share.

During the quarter, EVE recorded Research and Development payments of approximately $61,000, Manufacturing and operational expenditure of around $148,000, Advertising and Marketing costs of around $167,000, staff costs of around $166,000 and administration costs of approximately $79,000.

Based on the March 2026 quarterly cash flow rate, the company estimated funding availability of approximately five quarters, although this estimate does not include future costs associated with Libbo development.

What Comes Next?

The next key milestone for EVE (ASX:EVE) is the expected pilot study readout by the end of September 2026.

Positive pharmacokinetic and tolerability results would support progression toward designing the pivotal bioequivalence study required for potential regulatory registration.

The company has not disclosed specific timelines for the pivotal study, regulatory submissions or commercial launch.

Future updates will likely focus on pilot study outcomes, trial design progression and funding requirements as the Libbo program advances.

Risks

EVE (ASX:EVE) remains exposed to clinical development and funding risks. The pilot study may not provide sufficient data to support progression to a pivotal bioequivalence trial, or formulation changes may be required. The company has a limited cash position and may require additional capital to progress Libbo and other pipeline products. Commercial success depends on regulatory approval, market access and competition within the erectile dysfunction treatment market.

Investor Takeaway

EVE Health Group has reached the first clinical milestone for Libbo by commencing a pilot pharmacokinetic study of its oral soluble vardenafil film.

The study provides initial data needed to design a larger bioequivalence trial, but it does not represent a registration milestone or commercial approval.

For EVE (ASX:EVE), the September 2026 pilot results will be the next important update, while funding management and progression of the broader reformulation pipeline will remain key factors as the company advances its development programs.